Development and psychometric evaluation of the Treatment Adherence Questionnaire for Patients with Hypertension

Ma, Chunhua; Chen, Shaoxian; You, Liming; Luo, Zhimin; Caixia, Xing

doi:10.1111/j.1365-2648.2011.05835.x

Cited by 45 publications

(54 citation statements)

References 20 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In China alone, approximately 200 million people suffer from hypertension [1]. Although various therapeutic antihypertensive drugs have been developed to treat and reduce blood pressure, the complications associated with hypertension are harder to treat and remain mostly intractable in the clinic.…”

Section: Introductionmentioning

confidence: 99%

Pirfenidone Attenuates Cardiac Fibrosis in a Mouse Model of TAC-Induced Left Ventricular Remodeling by Suppressing NLRP3 Inflammasome Formation

Wang¹,

Wu²,

Chen³

et al. 2013

Cardiology

127

View full text Add to dashboard Cite

Objectives: Left ventricular remodeling is a frequent complication of hypertension with no therapeutic treatment available for the subsequent onset of myocardial fibrosis. Pirfenidone is an antifibrotic small-molecular-size drug with anti-inflammatory properties that is used as a treatment for fibrotic diseases, but its effects on hypertension-induced myocardial fibrosis are unknown. Therefore, we tested whether pirfenidone could ameliorate hypertension-induced left ventricular remodeling and whether hypertension-induced NLRP3 (Nod-like receptor pyrin domain containing 3), a critical protein in NLRP3 inflammasome formation, is involved in the therapeutic mechanism. Methods: A TAC-induced mouse model of hypertension and left ventricular hypertrophy was treated with pirfenidone, and survival, collagen deposition by histopathologic examination, heart function by echocardiography, concentrations of fibrosis-related inflammatory cytokines TGF-β₁, IL-1β in heart homogenate and in vitro cell cultures by ELISA, levels of ROS and inflammatory cells by flow cytometry, and levels of NLRP3 by Western blotting and immunohistochemistry were measured. Results: Pirfenidone increased the survival rate and attenuated myocardial fibrosis and inflammatory mediators in the TAC-induced hypertension-complicated left ventricular remodeling mouse model. The inhibition of NLRP3 expression by pirfenidone attenuated the expression of IL-1β and IL-1β-induced inflammatory and profibrotic responses. Conclusions: Pirfenidone may be useful in the treatment of hypertension-induced myocardial fibrosis by inhibiting NLRP3-induced inflammation and fibrosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Pirfenidone Attenuates Cardiac Fibrosis in a Mouse Model of TAC-Induced Left Ventricular Remodeling by Suppressing NLRP3 Inflammasome Formation

Wang¹,

Wu²,

Chen³

et al. 2013

Cardiology

127

View full text Add to dashboard Cite

show abstract

“…Ma et al [66] developed and tested the Treatment Adherence Questionnaire for Patients with Hypertension (TAQPH). The TAQPH consists of six subscales with 28 items.…”

Section: Treatment Adherence Questionnaire For Patients With Hypertenmentioning

confidence: 99%

“…The Cronbach's alpha coefficient of the overall questionnaire was 0.86 and 0.82 for test-retest reliability. The authors concluded that the TAQPH can be applied for research and clinical purposes [66].…”

Section: Treatment Adherence Questionnaire For Patients With Hypertenmentioning

confidence: 99%

“…So far, this is the most extensively studied scale, validated for a large number of diseases [35][36][37][38][39][40][41][42][43][44][45][46][47][48][49]. The Self-efficacy for Appropriate Medication Use (SEAMS) [50][51], the Hill-Bone Compliance Scale [52][53][54][55], the Brief Medication Questionnaire (BMQ) [56][57][58][59], the Treatment Adherence Questionnaire for Patients with Hypertension (TAQPH) [66], the Martin-Bayarre-Grau questionnaire (MBG) [67][68], and the Adherence Self-Report Questionnaire (ASRQ) [69] focus on patients with chronic cardiovascular diseases, mainly with hypertension. The Adherence in Chronic Diseases Scale (ACDS) is also designed for examining chronically ill, adult patients; however, it was validated and subsequently applied only in patients after myocardial infarction.…”

Section: Expert Opinionmentioning

confidence: 99%

See 1 more Smart Citation

Self-reported questionnaires for assessment adherence to treatment in patients with cardiovascular diseases

Kubica

Kosobucka

Michalski

et al. 2018

Medical Research Journal

View full text Add to dashboard Cite

show abstract

“…Hypertension is now considered a major public health issue [1] that affects nearly one billion people worldwide [2]. It is recognized as the leading contributor to death and disability globally [3], and the prevalence is dramatically increasing [4,5].…”

Section: Introductionmentioning

confidence: 99%

The A930G Polymorphism of P22phox (CYBA) Gene but Not C242T Variation Is Associated with Hypertension: A Meta-Analysis

et al. 2013

View full text Add to dashboard Cite

BackgroundRecently, it has been reported that the A930G and C242T polymorphisms within p22phox (CYBA) gene are involved in the pathogenesis of hypertension. However, the results remain controversial. Furthermore, no previous meta-analysis has been conducted to evaluate the relationship between the A930G and C242T polymorphisms and hypertension. Therefore, we performed this meta-analysis to clarify these controversies.Objective and MethodsAll of the included articles were retrieved from the PubMed and Embase databases, as well as the CNKI, CBM, Chongqing VIP and Wan Fang databases according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Odds ratios (OR) with corresponding 95% confidence intervals (CI) were used to assess the strength of the association. Accounting for heterogeneity, a fixed or random effects model was respectively adopted. Heterogeneity was checked using the Q test and the I2 statistic. A cumulative meta-analysis was conducted to estimate the tendency of pooled OR. Funnel plots and Egger’s tests were performed to test for possible publication bias.ResultsFive articles on A930G with 2003 cases/2434 controls and eight articles on C242T with 2644 cases/1967 controls were identiﬁed. A signiﬁcant association of A930G polymorphisms with the risk of hypertension was found in the dominant model (OR=0.59, 95% CI: 0.38–0.92, p=0.021) and allelic model (OR=0.66, 95% CI: 0.46–0.95, p=0.024). In the stratified analysis, a signiﬁcant association could be found among the hospital-based and population-based studies. However, no evidence of a significant association of the C242T polymorphism with hypertension was found in the overall analysis and subgroup analysis.ConclusionsThis meta-analysis indicates that the A930G polymorphism, but not the C242T variation, might be a protective factor for hypertension.

show abstract

Development and psychometric evaluation of the Treatment Adherence Questionnaire for Patients with Hypertension

Abstract: The questionnaire was a brief and psychometrically sound instrument to evaluate hypertensive patients' treatment adherence and to be applied in the research and clinical fields.

Cited by 45 publications

References 20 publications

Pirfenidone Attenuates Cardiac Fibrosis in a Mouse Model of TAC-Induced Left Ventricular Remodeling by Suppressing NLRP3 Inflammasome Formation

Pirfenidone Attenuates Cardiac Fibrosis in a Mouse Model of TAC-Induced Left Ventricular Remodeling by Suppressing NLRP3 Inflammasome Formation

Self-reported questionnaires for assessment adherence to treatment in patients with cardiovascular diseases

The A930G Polymorphism of P22phox (CYBA) Gene but Not C242T Variation Is Associated with Hypertension: A Meta-Analysis

Contact Info

Product

Resources

About